MedTrace Logo

Platelet and Immune Response in Covid-19 Vaccine

NCT05171959 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2021-12-29

No results posted yet for this study

Summary

COVID-19 mRNA vaccines, administered with a two-dose regimen, have been shown to provide protection against Covid-19. However, the thromboinflammatory response toward these vaccines has never been explored as they exploit a completely new technology. It was reported that mRNA vaccines are highly reactogenic right after vaccine administration in particular in young adults, but we do not know which cells drive the early immune response to LNP-mRNA vaccines in humans and if platelets become activated as well. Moreover, it is not known if female, who have a heightened immune response to other vaccines, are able to mount a faster response to this new type of vaccines.

Objectives of the study is to characterize the platelet and immune response and the platelet-immune cross-talk in subjects undergoing SARS-CoV-2 vaccination.

Conditions

  • SARS-CoV-2 Vaccination

Sponsors & Collaborators

  • Lucia Stefanini

    collaborator UNKNOWN

  • Stefania Basili

    collaborator UNKNOWN

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Roberto Cangemi, MD · University of Roma La Sapienza

  • Stefania Basili, MD · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2022-02-15
Completion
2022-04-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171959 on ClinicalTrials.gov